Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Capital Expenditures (2016 - 2025)

Capricor Therapeutics has reported Capital Expenditures over the past 14 years, most recently at $1.7 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $1.7 million for Q4 2025, up 240.61% from a year ago — trailing twelve months through Dec 2025 was $2.9 million (up 148.91% YoY), and the annual figure for FY2025 was $2.9 million, up 148.91%.
  • Capital Expenditures for Q4 2025 was $1.7 million at Capricor Therapeutics, up from $55843.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for CAPR hit a ceiling of $1.7 million in Q4 2025 and a floor of $9145.0 in Q3 2024.
  • Median Capital Expenditures over the past 5 years was $358180.5 (2021), compared with a mean of $428976.0.
  • Biggest five-year swings in Capital Expenditures: soared 1437.75% in 2022 and later plummeted 96.61% in 2024.
  • Capricor Therapeutics' Capital Expenditures stood at $368671.0 in 2021, then surged by 88.26% to $694044.0 in 2022, then dropped by 19.51% to $558604.0 in 2023, then dropped by 12.5% to $488798.0 in 2024, then skyrocketed by 240.61% to $1.7 million in 2025.
  • The last three reported values for Capital Expenditures were $1.7 million (Q4 2025), $55843.0 (Q3 2025), and $287738.0 (Q2 2025) per Business Quant data.